Literature DB >> 16014533

Value of a new automated fluorescence immunoassay (EliA) for PR3 and MPO-ANCA in monitoring disease activity in ANCA-associated systemic vasculitis.

Renato Alberto Sinico1, Antonella Radice, Caterina Corace, Lucafrancesco DI Toma, Ettore Sabadini.   

Abstract

The value of anti-neutrophil cytoplasmic antibody (ANCA) detection for monitoring disease activity in ANCA-associated systemic vasculitis (AASV) remains controversial. The aim of our work was to rate the performance of a new automated fluorescence PR3 and MPO-ANCA immunoassay (EliA) for monitoring disease activity in AASV. We evaluated 100 serum samples from 71 AASV patients (with Wegener's granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome) as well as sera from 58 pathological and 35 normal controls. In addition to PR3 and MPO-ANCA EliA, we performed indirect immunofluorescence and "homemade" PR3 and MPO-ANCA ELISA tests. In AASV patients, ANCA levels were correlated with disease activity, according to the Birmingham Vasculitis Activity Score (BVAS). We derived cutoff limits from receiver operating characteristic (ROC) curve analysis comparing AASV with pathological controls. Our results showed that EliA and ELISA had comparable sensitivity (76%) and specificity (95%). The analysis of active versus inactive status and correlation with ANCA levels showed a clear difference between BVAS Group I (score < or = 4) and BVAS Group II (scores > 4) (AUC = 0.86 vs. 0.72; relative risk [RR] = 2.4; P < 0.0001) for PR3-ANCA, but not for MPO-ANCA (AUC = 0.94 vs. 0.87; RR = 1.48; P = 0.46). Serial serum samples from 16 patients were examined in detail. For the majority of patients, for both PR3 and MPO-ANCA, change in titer was strongly associated with change in BVAS score. Our data showed a good correlation between ANCA titer (especially for PR3) and AASV disease activity. We recommend that ANCA titer be used to monitor AASV disease activity with the caveat that a few exceptions, in particular with MPO-ANCA, are possible.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16014533     DOI: 10.1196/annals.1313.019

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

1.  Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria.

Authors:  Zoya Kuzmina; Verena Gounden; Lauren Curtis; Daniele Avila; Tiffani Taylor Rnp; Judy Baruffaldi; Edward W Cowen; Haley B Naik; Sarfaraz A Hasni; Jacqueline W Mays; Sandra Mitchell; Kristin Baird; Seth M Steinberg; Steven Z Pavletic
Journal:  Am J Hematol       Date:  2014-11-24       Impact factor: 10.047

2.  Potential value of autoantibodies as biomarkers of chronic graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Bing Hao; Song Gao; Yi-Wen Sang; Lin Wang; Xue-Qin Meng; Jing-Ya You
Journal:  J Zhejiang Univ Sci B       Date:  2019 Oct.       Impact factor: 3.066

Review 3.  [Paradigm shift in ANCA diagnostics : New international consensus recommendations].

Authors:  E Csernok; N Kempiners; B Hellmich
Journal:  Z Rheumatol       Date:  2017-03       Impact factor: 1.372

4.  Antineutrophil cytoplasmic antibodies and their relationship with disease activity and presence of staphylococcal superantigens in nasal swabs in patients having granulomatosis with polyangiitis: results of a study involving 115 patients from a single center.

Authors:  Justyna Fijolek; E Wiatr; V Petroniec; E Augustynowicz-Kopec; M Bednarek; D Gawryluk; K Roszkowski-Sliz
Journal:  Clin Rheumatol       Date:  2019-07-23       Impact factor: 2.980

5.  Macrophage migration inhibitory factor: a multifunctional cytokine in rheumatic diseases.

Authors:  Tsuyoshi Kasama; Kumiko Ohtsuka; Michihito Sato; Ryo Takahashi; Kuninobu Wakabayashi; Kazuo Kobayashi
Journal:  Arthritis       Date:  2010-12-26

6.  Increased serum levels of macrophage migration inhibitory factor (MIF) in patients with microscopic polyangiitis.

Authors:  Hirohito Kanemitsu; Mizuho Matsunawa; Kuninobu Wakabayashi; Michihito Sato; Ryo Takahashi; Tsuyoshi Odai; Takeo Isozaki; Nobuyuki Yajima; Yusuke Miwa; Tsuyoshi Kasama
Journal:  Open Access Rheumatol       Date:  2009-03-13

7.  First steps in the standardization of immunoglobulin IgG myeloperoxidase-anti-neutrophil cytoplasmic antibody measurements.

Authors:  D P Hutu; E Tuddenham; E Monogioudi; P Meroni; H Schimmel; J Sheldon; I Zegers
Journal:  Clin Exp Immunol       Date:  2015-11-18       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.